Medi Assist Healthcare Services Ltd Valuation Shifts Signal Price Attractiveness

Valuation Metrics: A Closer Look

As of 8 September 2026, Medi Assist’s P/E ratio stands at 25.07, a figure that has improved sufficiently to shift its valuation grade to “attractive” from the previous “fair” rating. This is particularly significant when compared to its peer group within the insurance sector, where many competitors are trading at substantially higher multiples. For instance, Mindspace Business Parks and Inventurus Knowledge Solutions are both classified as “very expensive,” with P/E ratios of 42.14 and 40.14 respectively. Similarly, Brookfield India and Cams Services trade at elevated valuations, with P/E ratios of 52.85 and 37.14.

In addition to the P/E ratio, Medi Assist’s price-to-book value ratio of 2.99 further supports the notion of improved price attractiveness. While not the lowest in its peer set, this P/BV is considerably more reasonable than many “very expensive” peers, which often command premiums well above 3.5 times book value. The company’s enterprise value to EBITDA (EV/EBITDA) ratio of 12.88 also compares favourably against peers such as Inventurus Knowledge Solutions (26.72) and Cams Services (24.69), underscoring a more balanced valuation relative to earnings before interest, tax, depreciation and amortisation.

Financial Performance and Returns

Despite the improved valuation metrics, Medi Assist’s recent stock performance has been underwhelming. The share price closed at ₹336.65 on 8 September 2026, down 1.10% on the day and significantly off its 52-week high of ₹575.95. Year-to-date, the stock has declined by 26.77%, markedly underperforming the Sensex’s 10.66% gain over the same period. Over the past year, the stock has fallen 35.13%, while the Sensex advanced 5.67%, highlighting the stock’s relative weakness amid broader market strength.

However, the company’s return on capital employed (ROCE) of 14.90% and return on equity (ROE) of 11.31% indicate solid operational efficiency and profitability. These metrics suggest that while the market has penalised the stock recently, the underlying business fundamentals remain intact. Investors may find comfort in these returns, which are respectable within the insurance sector, especially for a small-cap entity.

Comparative Valuation and Peer Analysis

When analysing Medi Assist’s valuation in the context of its peers, the company’s “attractive” grade stands out amid a landscape dominated by “very expensive” and “risky” classifications. For example, Sagility, another insurance sector player, also holds an “attractive” valuation with a P/E of 20.86 and EV/EBITDA of 11.74, slightly more conservative than Medi Assist but within a comparable range. On the other hand, BLS International is rated “very attractive” with a notably lower P/E of 14 and EV/EBITDA of 10.15, indicating even greater valuation appeal.

It is also important to note that some peers such as Urban Company are classified as “risky” due to loss-making status, which contrasts with Medi Assist’s positive earnings and profitability metrics. This relative stability in earnings and valuation metrics may provide a cushion for investors seeking exposure to the insurance sector without excessive risk.

Market Capitalisation and Analyst Ratings

Medi Assist is categorised as a small-cap company, which inherently carries higher volatility and growth potential compared to large-cap peers. The company’s Mojo Score currently stands at 48.0, with a Mojo Grade of “Sell,” upgraded from a previous “Strong Sell” on 2 December 2025. This upgrade reflects a modest improvement in sentiment, likely driven by the more attractive valuation parameters and stabilising fundamentals. However, the “Sell” rating indicates that caution remains warranted, and investors should weigh the risks carefully.

Valuation Multiples in Context

Examining the EV to EBIT and EV to Capital Employed ratios, Medi Assist reports values of 24.29 and 3.56 respectively. These figures suggest that while the company is not the cheapest in absolute terms, it offers a reasonable valuation relative to its earnings and capital base. The EV to Sales ratio of 2.45 further supports this view, indicating that the market is valuing the company at less than two and a half times its annual sales, a moderate multiple for the insurance sector.

The PEG ratio of 4.20, however, remains elevated, signalling that the stock’s price still factors in relatively high growth expectations. This contrasts with some peers like Sagility (PEG 0.38) and BLS International (PEG 0.56), which trade at more modest growth premiums. Investors should consider whether Medi Assist’s growth prospects justify this premium or if the valuation still leaves room for downside risk.

Stock Price Volatility and Trading Range

The stock’s 52-week trading range between ₹293.40 and ₹575.95 highlights significant volatility, with the current price near the lower end of this spectrum. Daily trading on 8 September 2026 saw a high of ₹343.30 and a low of ₹333.00, reflecting a relatively narrow intraday range but a downward bias overall. This price action suggests that while the stock has stabilised somewhat after steep declines, investor confidence remains tentative.

Investment Outlook and Conclusion

Medi Assist Healthcare Services Ltd’s recent valuation improvements offer a more attractive entry point for investors willing to look beyond short-term price weakness. The company’s P/E and P/BV ratios now compare favourably within its peer group, and its profitability metrics remain solid despite a challenging market environment. However, the elevated PEG ratio and ongoing “Sell” Mojo Grade suggest that growth expectations remain high and risks persist.

Investors should balance the company’s improved valuation against its recent underperformance and sector dynamics. While the stock’s small-cap status offers growth potential, it also entails volatility and sensitivity to market sentiment. Those considering exposure to the insurance sector may find Medi Assist’s valuation compelling relative to more expensive peers, but should remain vigilant for further developments in earnings and market conditions.

Overall, the shift from a fair to an attractive valuation grade marks a meaningful change in Medi Assist’s price attractiveness, signalling a potential opportunity for value-oriented investors to reassess the stock within a broader portfolio context.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today